{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:23:10Z","timestamp":1790464990337,"version":"4.1.0"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40257-020-00502-6","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T03:05:45Z","timestamp":1582513545000},"page":"339-353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Dermatomyositis: An Update on Diagnosis and Treatment"],"prefix":"10.1007","volume":"21","author":[{"given":"Gabriela A.","family":"Cobos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Femia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-7115","authenticated-orcid":false,"given":"Ruth Ann","family":"Vleugels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"issue":"1","key":"502_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","volume":"146","author":"MJ Bendewald","year":"2010","unstructured":"Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26\u201330. https:\/\/doi.org\/10.1001\/archdermatol.2009.328.","journal-title":"Arch Dermatol"},{"issue":"6","key":"502_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3109\/09546634.2012.697540","volume":"24","author":"LC Strowd","year":"2013","unstructured":"Strowd LC, Jorizzo JL. Review of dermatomyositis: establishing the diagnosis and treatment algorithm. J Dermatol Treat. 2013;24(6):418\u201321. https:\/\/doi.org\/10.3109\/09546634.2012.697540.","journal-title":"J Dermatol Treat"},{"key":"502_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jaut.2013.11.005","volume":"48\u201349","author":"L Iaccarino","year":"2014","unstructured":"Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L, et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun. 2014;48\u201349:122\u20137. https:\/\/doi.org\/10.1016\/j.jaut.2013.11.005.","journal-title":"J Autoimmun"},{"issue":"1","key":"502_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/bjd.14227","volume":"174","author":"F Galimberti","year":"2016","unstructured":"Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016;174(1):158\u201364. https:\/\/doi.org\/10.1111\/bjd.14227.","journal-title":"Br J Dermatol"},{"issue":"3","key":"502_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11926-011-0166-x","volume":"13","author":"L Kao","year":"2011","unstructured":"Kao L, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep. 2011;13(3):225\u201332. https:\/\/doi.org\/10.1007\/s11926-011-0166-x.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"502_CR6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.15006","volume":"176","author":"C Huard","year":"2017","unstructured":"Huard C, Gulla SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis. Br J Dermatol. 2017;176(5):1224\u201330. https:\/\/doi.org\/10.1111\/bjd.15006.","journal-title":"Br J Dermatol"},{"issue":"3","key":"502_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11926-010-0100-7","volume":"12","author":"JP Callen","year":"2010","unstructured":"Callen JP. Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep. 2010;12(3):192\u20137. https:\/\/doi.org\/10.1007\/s11926-010-0100-7.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"502_CR8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1517\/14656566.5.5.1083","volume":"5","author":"RD Sontheimer","year":"2004","unstructured":"Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother. 2004;5(5):1083\u201399. https:\/\/doi.org\/10.1517\/14656566.5.5.1083.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"502_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0733-8635(02)00021-9","volume":"20","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20(3):387\u2013408.","journal-title":"Dermatol Clin"},{"issue":"4","key":"502_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626\u201336.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"502_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","volume":"54","author":"P Gerami","year":"2006","unstructured":"Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597\u2013613. https:\/\/doi.org\/10.1016\/j.jaad.2005.10.041.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"502_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40257-013-0028-6","volume":"14","author":"AN Femia","year":"2013","unstructured":"Femia AN, Vleugels RA, Callen JP. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol. 2013;14(4):291\u2013313. https:\/\/doi.org\/10.1007\/s40257-013-0028-6.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"502_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jaad.2007.08.024","volume":"57","author":"RQ Klein","year":"2007","unstructured":"Klein RQ, Teal V, Taylor L, Troxel AB, Werth VP. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol. 2007;57(6):937\u201343. https:\/\/doi.org\/10.1016\/j.jaad.2007.08.024.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"502_CR14","doi-asserted-by":"publisher","first-page":"e9639","DOI":"10.1097\/md.0000000000009639","volume":"97","author":"H Leatham","year":"2018","unstructured":"Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, et al. Evidence supports blind screening for internal malignancy in dermatomyositis. Medicine. 2018;97(2):e9639. https:\/\/doi.org\/10.1097\/md.0000000000009639.","journal-title":"Medicine"},{"issue":"6","key":"502_CR15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","volume":"65","author":"R Goreshi","year":"2011","unstructured":"Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, et al. Quality of life in dermatomyositis. J Am Acad Dermatol. 2011;65(6):1107\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2010.10.016.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"502_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2017.3758","volume":"154","author":"PW Wolstencroft","year":"2018","unstructured":"Wolstencroft PW, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Factors associated with clinical remission of skin disease in dermatomyositis. JAMA Dermatol. 2018;154(1):44\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2017.3758.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"502_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaad.2017.12.074","volume":"79","author":"DM Da Silva","year":"2018","unstructured":"Da Silva DM, Patel B, Werth VP. Dermatomyositis: a diagnostic dilemma. J Am Acad Dermatol. 2018;79(2):371\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.074.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"502_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJM199202063260602","volume":"326","author":"B Sigurgeirsson","year":"1992","unstructured":"Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study. N Engl J Med. 1992;326(6):363\u20137. https:\/\/doi.org\/10.1056\/NEJM199202063260602.","journal-title":"N Engl J Med"},{"issue":"2","key":"502_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3899\/jrheum.140566","volume":"42","author":"Z Yang","year":"2015","unstructured":"Yang Z, Lin F, Qin B, Liang Y, Zhong R. Polymyositis\/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282\u201391. https:\/\/doi.org\/10.3899\/jrheum.140566.","journal-title":"J Rheumatol"},{"issue":"1","key":"502_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/DAD.0b013e31818520e1","volume":"31","author":"ES Smith","year":"2009","unstructured":"Smith ES, Hallman JR, DeLuca AM, Goldenberg G, Jorizzo JL, Sangueza OP. Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol. 2009;31(1):61\u20137. https:\/\/doi.org\/10.1097\/DAD.0b013e31818520e1.","journal-title":"Am J Dermatopathol"},{"issue":"5","key":"502_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.semarthrit.2016.11.001","volume":"46","author":"J Day","year":"2017","unstructured":"Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;46(5):642\u20139. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.11.001.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"502_CR22","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/ard.2008.097162","volume":"68","author":"ZE Betteridge","year":"2009","unstructured":"Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009;68(10):1621\u20135. https:\/\/doi.org\/10.1136\/ard.2008.097162.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"502_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/art.33402","volume":"64","author":"D Fiorentino","year":"2012","unstructured":"Fiorentino D, Casciola-Rosen L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum. 2012;64(2):346\u20139. https:\/\/doi.org\/10.1002\/art.33402.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"502_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a\u00a0retrospective study. J Am Acad Dermatol. 2011;65(1):25\u201334. https:\/\/doi.org\/10.1016\/j.jaad.2010.09.016.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"502_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/annrheumdis-2012-201736","volume":"72","author":"M Fujimoto","year":"2013","unstructured":"Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, Ogawa F, et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis. 2013;72(1):151\u20133. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201736.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"502_CR26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","volume":"28","author":"M Fujimoto","year":"2016","unstructured":"Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28(6):636\u201344. https:\/\/doi.org\/10.1097\/BOR.0000000000000329.","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"502_CR27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","volume":"78","author":"DJB Kurtzman","year":"2018","unstructured":"Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78(4):776\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.010.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"502_CR28","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.chest.2017.05.015","volume":"152","author":"TJ Doyle","year":"2017","unstructured":"Doyle TJ, Dellaripa PF. Lung manifestations in the rheumatic diseases. Chest. 2017;152(6):1283\u201395. https:\/\/doi.org\/10.1016\/j.chest.2017.05.015.","journal-title":"Chest"},{"issue":"5","key":"502_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11926-018-0731-7","volume":"20","author":"CA Mecoli","year":"2018","unstructured":"Mecoli CA, Christopher-Stine L. Management of interstitial lung disease in patients with myositis specific autoantibodies. Curr Rheumatol Rep. 2018;20(5):27. https:\/\/doi.org\/10.1007\/s11926-018-0731-7.","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"502_CR30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/archdermatol.2010.134","volume":"146","author":"PA Morganroth","year":"2010","unstructured":"Morganroth PA, Kreider ME, Okawa J, Taylor L, Werth VP. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol. 2010;146(7):729\u201338. https:\/\/doi.org\/10.1001\/archdermatol.2010.134.","journal-title":"Arch Dermatol"},{"issue":"5","key":"502_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","volume":"20","author":"PW Wolstencroft","year":"2018","unstructured":"Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20(5):28. https:\/\/doi.org\/10.1007\/s11926-018-0733-5.","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"502_CR32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.clindermatol.2018.04.008","volume":"36","author":"DM Tartar","year":"2018","unstructured":"Tartar DM, Chung L, Fiorentino DF. Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. Clin Dermatol. 2018;36(4):508\u201324. https:\/\/doi.org\/10.1016\/j.clindermatol.2018.04.008.","journal-title":"Clin Dermatol"},{"issue":"4","key":"502_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","volume":"147","author":"Y Hamaguchi","year":"2011","unstructured":"Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147(4):391\u20138. https:\/\/doi.org\/10.1001\/archdermatol.2011.52.","journal-title":"Arch Dermatol"},{"issue":"7","key":"502_CR34","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00296-016-3494-3","volume":"36","author":"P Srivastava","year":"2016","unstructured":"Srivastava P, Dwivedi S, Misra R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int. 2016;36(7):935\u201343. https:\/\/doi.org\/10.1007\/s00296-016-3494-3.","journal-title":"Rheumatol Int"},{"issue":"3","key":"502_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jdermsci.2005.09.004","volume":"40","author":"K Komura","year":"2005","unstructured":"Komura K, Fujimoto M, Matsushita T, Kaji K, Kondo M, Hirano T, et al. Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci. 2005;40(3):215\u20137. https:\/\/doi.org\/10.1016\/j.jdermsci.2005.09.004.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"502_CR36","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1186\/ar4207","volume":"15","author":"MH Petri","year":"2013","unstructured":"Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramirez R, Jara LJ, Saavedra MA, et al. Implications in the difference of anti-Mi-2 and -p155\/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther. 2013;15(2):R48. https:\/\/doi.org\/10.1186\/ar4207.","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"502_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/ard.2005.040717","volume":"65","author":"GJ Hengstman","year":"2006","unstructured":"Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis. 2006;65(2):242\u20135. https:\/\/doi.org\/10.1136\/ard.2005.040717.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"502_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","volume":"56","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017;56(2):247\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/kew396.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"502_CR39","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.autrev.2014.08.011","volume":"13","author":"L Bodoki","year":"2014","unstructured":"Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szollosi L, Danko K. Four dermatomyositis-specific autoantibodies-anti-TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev. 2014;13(12):1211\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.011.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"502_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/08916934.2012.755958","volume":"46","author":"Y Muro","year":"2013","unstructured":"Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity. 2013;46(4):279\u201384. https:\/\/doi.org\/10.3109\/08916934.2012.755958.","journal-title":"Autoimmunity."},{"key":"502_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","volume":"7","author":"Y Ge","year":"2017","unstructured":"Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep. 2017;7:188.","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"502_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jim.2012.07.019","volume":"384","author":"E Tarricone","year":"2012","unstructured":"Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods. 2012;384(1\u20132):128\u201334. https:\/\/doi.org\/10.1016\/j.jim.2012.07.019.","journal-title":"J Immunol Methods"},{"issue":"4","key":"502_CR43","doi-asserted-by":"publisher","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","volume":"8","author":"Y Hamaguchi","year":"2013","unstructured":"Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 2013;8(4):e60442. https:\/\/doi.org\/10.1371\/journal.pone.0060442.","journal-title":"PLoS One"},{"issue":"9","key":"502_CR44","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","volume":"13","author":"JC Lega","year":"2014","unstructured":"Lega JC, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev. 2014;13(9):883\u201391. https:\/\/doi.org\/10.1016\/j.autrev.2014.03.004.","journal-title":"Autoimmun Rev"},{"key":"502_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"H Hozumi","year":"2016","unstructured":"Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91\u20139. https:\/\/doi.org\/10.1016\/j.rmed.2016.10.019.","journal-title":"Respir Med"},{"issue":"9","key":"502_CR46","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s10067-015-2935-9","volume":"34","author":"Z Chen","year":"2015","unstructured":"Chen Z, Hu W, Wang Y, Guo Z, Sun L, Kuwana M. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis. Clin Rheumatol. 2015;34(9):1627\u201331. https:\/\/doi.org\/10.1007\/s10067-015-2935-9.","journal-title":"Clin Rheumatol"},{"issue":"44","key":"502_CR47","doi-asserted-by":"publisher","first-page":"76129","DOI":"10.18632\/oncotarget.19050","volume":"8","author":"L Li","year":"2017","unstructured":"Li L, Wang Q, Wen X, Liu C, Wu C, Yang F, et al. Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease. Oncotarget. 2017;8(44):76129\u201340. https:\/\/doi.org\/10.18632\/oncotarget.19050.","journal-title":"Oncotarget."},{"issue":"8","key":"502_CR48","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/acr.21992","volume":"65","author":"JC Hall","year":"2013","unstructured":"Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65(8):1307\u201315. https:\/\/doi.org\/10.1002\/acr.21992.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"502_CR49","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","volume":"72","author":"DF Fiorentino","year":"2015","unstructured":"Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2014.12.009.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"502_CR50","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.33403","volume":"64","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al. Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64(2):513\u201322. https:\/\/doi.org\/10.1002\/art.33403.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"502_CR51","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/bjd.15468","volume":"177","author":"S Meisterfeld","year":"2017","unstructured":"Meisterfeld S, Rober N, Conrad K, Beissert S, Aringer M, Gunther C. A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1-gamma. Br J Dermatol. 2017;177(2):590\u20133. https:\/\/doi.org\/10.1111\/bjd.15468.","journal-title":"Br J Dermatol"},{"issue":"10","key":"502_CR52","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/jamadermatol.2018.2549","volume":"154","author":"PW Wolstencroft","year":"2018","unstructured":"Wolstencroft PW, Casciola-Rosen L, Fiorentino DF. Association between autoantibody phenotype and cutaneous adverse reactions to hydroxychloroquine in dermatomyositis. JAMA Dermatol. 2018;154(10):1199\u2013203. https:\/\/doi.org\/10.1001\/jamadermatol.2018.2549.","journal-title":"JAMA Dermatol."},{"issue":"1","key":"502_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","volume":"46","author":"K Kaji","year":"2007","unstructured":"Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, et al. Identification of a novel autoantibody reactive with 155 and 140\u00a0kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007;46(1):25\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kel161.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"502_CR54","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1002\/art.22164","volume":"54","author":"IN Targoff","year":"2006","unstructured":"Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O\u2019Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682\u20139. https:\/\/doi.org\/10.1002\/art.22164.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"502_CR55","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/art.33379","volume":"64","author":"E Trallero-Araguas","year":"2012","unstructured":"Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O\u2019Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523\u201332. https:\/\/doi.org\/10.1002\/art.33379.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"502_CR56","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamadermatol.2016.1429","volume":"152","author":"LL Bernet","year":"2016","unstructured":"Bernet LL, Lewis MA, Rieger KE, Casciola-Rosen L, Fiorentino DF. Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1gamma (p155) antibodies. JAMA Dermatol. 2016;152(9):1049\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2016.1429.","journal-title":"JAMA Dermatol."},{"issue":"12","key":"502_CR57","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/acr.23210","volume":"69","author":"A Rogers","year":"2017","unstructured":"Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909\u201314. https:\/\/doi.org\/10.1002\/acr.23210.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"11","key":"502_CR58","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(11):1771\u20136. https:\/\/doi.org\/10.1002\/acr.23188.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"7","key":"502_CR59","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamadermatol.2013.10416","volume":"150","author":"A Valenzuela","year":"2014","unstructured":"Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol. 2014;150(7):724\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2013.10416.","journal-title":"JAMA Dermatol."},{"issue":"7","key":"502_CR60","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/rheumatology\/kes033","volume":"51","author":"A Ishikawa","year":"2012","unstructured":"Ishikawa A, Muro Y, Sugiura K, Akiyama M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford). 2012;51(7):1181\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kes033.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"502_CR61","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","volume":"134","author":"R Buchbinder","year":"2001","unstructured":"Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med. 2001;134(12):1087\u201395.","journal-title":"Ann Intern Med"},{"issue":"1","key":"502_CR62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF00051675","volume":"6","author":"WH Chow","year":"1995","unstructured":"Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995;6(1):9\u201313.","journal-title":"Cancer Causes Control"},{"issue":"9250","key":"502_CR63","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96\u2013100. https:\/\/doi.org\/10.1016\/S0140-6736(00)03540-6.","journal-title":"Lancet"},{"issue":"1","key":"502_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","volume":"85","author":"D Stockton","year":"2001","unstructured":"Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001;85(1):41\u20135. https:\/\/doi.org\/10.1054\/bjoc.2001.1699.","journal-title":"Br J Cancer"},{"issue":"2","key":"502_CR65","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/ar2987","volume":"12","author":"YJ Chen","year":"2010","unstructured":"Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther. 2010;12(2):R70. https:\/\/doi.org\/10.1186\/ar2987.","journal-title":"Arthritis Res Ther."},{"issue":"4","key":"502_CR66","doi-asserted-by":"publisher","first-page":"e94128","DOI":"10.1371\/journal.pone.0094128","volume":"9","author":"X Lu","year":"2014","unstructured":"Lu X, Yang H, Shu X, Chen F, Zhang Y, Zhang S, et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One. 2014;9(4):e94128. https:\/\/doi.org\/10.1371\/journal.pone.0094128.","journal-title":"PLoS One"},{"issue":"11","key":"502_CR67","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1002\/art.38093","volume":"65","author":"DF Fiorentino","year":"2013","unstructured":"Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum. 2013;65(11):2954\u201362. https:\/\/doi.org\/10.1002\/art.38093.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"502_CR68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2165\/00128071-200607060-00002","volume":"7","author":"RD Quain","year":"2006","unstructured":"Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol. 2006;7(6):341\u201351. https:\/\/doi.org\/10.2165\/00128071-200607060-00002.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"502_CR69","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","volume":"54","author":"JL Hundley","year":"2006","unstructured":"Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, et al. Cutaneous symptoms of dermatomyositis significantly impact patients\u2019 quality of life. J Am Acad Dermatol. 2006;54(2):217\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2004.12.015.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"502_CR70","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjd.13915","volume":"173","author":"CO Anyanwu","year":"2015","unstructured":"Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015;173(4):969\u201374. https:\/\/doi.org\/10.1111\/bjd.13915.","journal-title":"Br J Dermatol"},{"issue":"3","key":"502_CR71","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaad.2017.10.022","volume":"79","author":"PB Chansky","year":"2018","unstructured":"Chansky PB, Olazagasti JM, Feng R, Werth VP. Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index. J Am Acad Dermatol. 2018;79(3):464\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.022(e2).","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"502_CR72","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","volume":"162","author":"M Yassaee","year":"2010","unstructured":"Yassaee M, Fiorentino D, Okawa J, Taylor L, Coley C, Troxel AB, et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol. 2010;162(3):669\u201373. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09521.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"502_CR73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2133.1994.tb08492.x","volume":"131","author":"WK Cheong","year":"1994","unstructured":"Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol. 1994;131(2):205\u20138.","journal-title":"Br J Dermatol"},{"issue":"2","key":"502_CR74","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1529-8019.2012.01491.x","volume":"25","author":"C Lam","year":"2012","unstructured":"Lam C, Vleugels RA. Management of cutaneous dermatomyositis. Dermatol Ther. 2012;25(2):112\u201334. https:\/\/doi.org\/10.1111\/j.1529-8019.2012.01491.x.","journal-title":"Dermatol Ther"},{"issue":"5","key":"502_CR75","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.clindermatol.2006.07.001","volume":"24","author":"JP Callen","year":"2006","unstructured":"Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006;24(5):363\u201373. https:\/\/doi.org\/10.1016\/j.clindermatol.2006.07.001.","journal-title":"Clin Dermatol"},{"issue":"3","key":"502_CR76","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2230.2004.01510.x","volume":"29","author":"Z Shirani","year":"2004","unstructured":"Shirani Z, Kucenic MJ, Carroll CL, Fleischer AB Jr, Feldman SR, Yosipovitch G, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol. 2004;29(3):273\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.2004.01510.x.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"502_CR77","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bjd.16498","volume":"179","author":"HJ Kim","year":"2018","unstructured":"Kim HJ, Zeidi M, Bonciani D, Pena SM, Tiao J, Sahu S, et al. Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol. 2018;179(3):669\u201378. https:\/\/doi.org\/10.1111\/bjd.16498.","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"502_CR78","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1136\/annrheumdis-2018-eular.3531","volume":"77","author":"VP Werth","year":"2018","unstructured":"Werth VP, Hejazi E, Pena SM, Haber JS, Okawa J, Feng R, et al. FRI0470\u2014a phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. Ann Rheum Dis. 2018;77(Suppl. 2):763\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.3531.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 2","key":"502_CR79","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/annrheumdis-2018-eular.5629","volume":"77","author":"VP Werth","year":"2018","unstructured":"Werth VP, Patel B, Concha JS, Okawa J, Pearson D, Hejazi E, et al. SAT0512\u2014safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001. Ann Rheum Dis. 2018;77(Suppl. 2):1111\u20132. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.5629.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"502_CR80","first-page":"50","volume":"12","author":"T Yoshimasu","year":"2002","unstructured":"Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol. 2002;12(1):50\u20132.","journal-title":"Eur J Dermatol."},{"issue":"3","key":"502_CR81","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1046\/j.1365-2133.2003.05209_4.x","volume":"148","author":"M Ueda","year":"2003","unstructured":"Ueda M, Makinodan R, Matsumura M, Ichihashi M. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol. 2003;148(3):595\u20136.","journal-title":"Br J Dermatol"},{"issue":"9","key":"502_CR82","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1136\/ard.2004.032714","volume":"64","author":"CE Lampropoulos","year":"2005","unstructured":"Lampropoulos CE, D\u2019Cruz DP. Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis. 2005;64(9):1376\u20137. https:\/\/doi.org\/10.1136\/ard.2004.032714.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"502_CR83","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/09541440042000269","volume":"15","author":"CB Hollar","year":"2004","unstructured":"Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatol Treat. 2004;15(1):35\u20139. https:\/\/doi.org\/10.1080\/09541440042000269.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"502_CR84","doi-asserted-by":"publisher","first-page":"348","DOI":"10.5021\/ad.2011.23.3.348","volume":"23","author":"JE Kim","year":"2011","unstructured":"Kim JE, Jeong MG, Lee HE, Ko JY, Ro YS. Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann Dermatol. 2011;23(3):348\u201351. https:\/\/doi.org\/10.5021\/ad.2011.23.3.348.","journal-title":"Ann Dermatol"},{"issue":"3","key":"502_CR85","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000079903","volume":"209","author":"I Garcia-Doval","year":"2004","unstructured":"Garcia-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology. 2004;209(3):247\u20138. https:\/\/doi.org\/10.1159\/000079903.","journal-title":"Dermatology"},{"issue":"3","key":"502_CR86","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2165\/00002018-200831030-00001","volume":"31","author":"J Ring","year":"2008","unstructured":"Ring J, Mohrenschlager M, Henkel V. The US FDA \u2018black box\u2019 warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008;31(3):185\u201398. https:\/\/doi.org\/10.2165\/00002018-200831030-00001.","journal-title":"Drug Saf"},{"issue":"1 Suppl.","key":"502_CR87","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1067\/mjd.2001.109817","volume":"44","author":"NA Soter","year":"2001","unstructured":"Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44(1 Suppl.):S39\u201346.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"502_CR88","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1610-0387.2010.07490.x","volume":"8","author":"FR Ochsendorf","year":"2010","unstructured":"Ochsendorf FR. Use of antimalarials in dermatology. Journal der Deutschen Dermatologischen Gesellschaft. 2010;8(10):829\u201344. https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07490.x(quiz 45).","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"4","key":"502_CR89","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0190-9622(84)80263-7","volume":"10","author":"TY Woo","year":"1984","unstructured":"Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10(4):592\u2013600.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"502_CR90","first-page":"1214","volume":"12","author":"WD James","year":"1985","unstructured":"James WD, Dawson N, Rodman OG. The treatment of dermatomyositis with hydroxchloroquine. J Rheumatol. 1985;12(6):1214\u20136.","journal-title":"J Rheumatol"},{"issue":"12","key":"502_CR91","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/archderm.1995.01690240035006","volume":"131","author":"A Cosnes","year":"1995","unstructured":"Cosnes A, Amaudric F, Gherardi R, Verroust J, Wechsler J, Revuz J, et al. Dermatomyositis without muscle weakness: long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol. 1995;131(12):1381\u20135.","journal-title":"Arch Dermatol"},{"issue":"6","key":"502_CR92","first-page":"1016","volume":"132","author":"NH Cox","year":"1995","unstructured":"Cox NH. Amyopathic dermatomyositis, photosensitivity and hydroxychloroquine. Br J Dermatol. 1995;132(6):1016\u20137.","journal-title":"Br J Dermatol"},{"issue":"3","key":"502_CR93","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0190-9622(98)70496-7","volume":"38","author":"MA Dawkins","year":"1998","unstructured":"Dawkins MA, Jorizzo JL, Walker FO, Albertson D, Sinal SH, Hinds A. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol. 1998;38(3):397\u2013404.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"502_CR94","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1001\/jamadermatol.2018.5215","volume":"155","author":"J Pinard","year":"2019","unstructured":"Pinard J, Femia AN, Roman M, Alsarheed A, Joyce C, Lin J, et al. Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers. JAMA Dermatol. 2019;155(4):494\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5215.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"502_CR95","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/archderm.138.9.1231","volume":"138","author":"MT Pelle","year":"2002","unstructured":"Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138(9):1231\u20133 (discussion 3).","journal-title":"Arch Dermatol"},{"issue":"4","key":"502_CR96","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijwd.2017.05.001","volume":"3","author":"CO Anyanwu","year":"2017","unstructured":"Anyanwu CO, Chansky PB, Feng R, Carr K, Okawa J, Werth VP. The systemic management of cutaneous dermatomyositis: results of a stepwise strategy. Int J Womens Dermatol. 2017;3(4):189\u201394. https:\/\/doi.org\/10.1016\/j.ijwd.2017.05.001.","journal-title":"Int J Womens Dermatol"},{"issue":"7","key":"502_CR97","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/archderm.141.7.855","volume":"141","author":"GC Ang","year":"2005","unstructured":"Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol. 2005;141(7):855\u20139. https:\/\/doi.org\/10.1001\/archderm.141.7.855.","journal-title":"Arch Dermatol"},{"issue":"6","key":"502_CR98","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386\u201394. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.058.","journal-title":"Ophthalmology"},{"issue":"3","key":"502_CR99","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/0002-9343(87)90444-x","volume":"82","author":"ML Estes","year":"1987","unstructured":"Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirey E, et al. Chloroquine neuromyotoxicity: clinical and pathologic perspective. Am J Med. 1987;82(3):447\u201355. https:\/\/doi.org\/10.1016\/0002-9343(87)90444-x.","journal-title":"Am J Med"},{"key":"502_CR100","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/978-1-4615-2584-4_89","volume":"370","author":"BN Cronstein","year":"1994","unstructured":"Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol. 1994;370:411\u20136.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"502_CR101","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/WCO.0b013e32834a9589","volume":"24","author":"MC Dalakas","year":"2011","unstructured":"Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011;24(5):457\u201362. https:\/\/doi.org\/10.1097\/WCO.0b013e32834a9589.","journal-title":"Curr Opin Neurol"},{"issue":"7566","key":"502_CR102","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(68)90649-1","volume":"2","author":"AN Malaviya","year":"1968","unstructured":"Malaviya AN, Many A, Schwartz RS. Treatment of dermatomyositis with methotrexate. Lancet. 1968;2(7566):485\u20138.","journal-title":"Lancet"},{"issue":"2","key":"502_CR103","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00124743-199504000-00007","volume":"1","author":"ED Newman","year":"1995","unstructured":"Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol. 1995;1(2):99\u2013102.","journal-title":"J Clin Rheumatol."},{"issue":"5 Pt 1","key":"502_CR104","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/0190-9622(95)91455-2","volume":"32","author":"ME Zieglschmid-Adams","year":"1995","unstructured":"Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995;32(5 Pt 1):754\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"502_CR105","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0190-9622(97)70327-X","volume":"36","author":"JS Kasteler","year":"1997","unstructured":"Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36(1):67\u201371.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"502_CR106","first-page":"130","volume":"38","author":"ME Zieglschmid-Adams","year":"1998","unstructured":"Zieglschmid-Adams ME, Pandya A, Cohen SB, Sontheimer RD. The value of methotrexate in dermatomyositis. J Am Acad Dermatol. 1998;38(1):130\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"502_CR107","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2230.2011.04188.x","volume":"37","author":"T Hornung","year":"2012","unstructured":"Hornung T, Ko A, Tuting T, Bieber T, Wenzel J. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol. 2012;37(2):139\u201342. https:\/\/doi.org\/10.1111\/j.1365-2230.2011.04188.x.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"502_CR108","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0889-857X(05)70366-5","volume":"23","author":"GW Cannon","year":"1997","unstructured":"Cannon GW. Methotrexate pulmonary toxicity. Rheum Dis Clin N Am. 1997;23(4):917\u201337.","journal-title":"Rheum Dis Clin N Am"},{"issue":"4","key":"502_CR109","first-page":"645","volume":"31","author":"M Hoekstra","year":"2004","unstructured":"Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645\u20138.","journal-title":"J Rheumatol"},{"issue":"3","key":"502_CR110","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11940-011-0119-8","volume":"13","author":"MC Dalakas","year":"2011","unstructured":"Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Options Neurol. 2011;13(3):311\u201323. https:\/\/doi.org\/10.1007\/s11940-011-0119-8.","journal-title":"Curr Treat Options Neurol"},{"issue":"5 Pt 1","key":"502_CR111","first-page":"824","volume":"34","author":"LA Drake","year":"1996","unstructured":"Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol. 1996;34(5 Pt 1):824\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"502_CR112","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1586\/edm.09.52","volume":"4","author":"RA Vleugels","year":"2009","unstructured":"Vleugels RA, Callen JP. Dermatomyositis: current and future treatments. Expert Rev Dermatol. 2009;4:581\u201394.","journal-title":"Expert Rev Dermatol."},{"issue":"2","key":"502_CR113","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jaad.2008.08.049","volume":"60","author":"AK Orvis","year":"2009","unstructured":"Orvis AK, Wesson SK, Breza TS Jr, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60(2):183\u201399. https:\/\/doi.org\/10.1016\/j.jaad.2008.08.049(quiz 200\u20132).","journal-title":"J Am Acad Dermatol."},{"issue":"2\u20133","key":"502_CR114","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2\u20133):85\u2013118.","journal-title":"Immunopharmacology."},{"issue":"6","key":"502_CR115","first-page":"1542","volume":"27","author":"AC Gelber","year":"2000","unstructured":"Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000;27(6):1542\u20135.","journal-title":"J Rheumatol"},{"issue":"3","key":"502_CR116","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","volume":"44","author":"V Majithia","year":"2005","unstructured":"Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford). 2005;44(3):386\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keh499.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"502_CR117","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archderm.142.1.65","volume":"142","author":"JC Edge","year":"2006","unstructured":"Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142(1):65\u20139. https:\/\/doi.org\/10.1001\/archderm.142.1.65.","journal-title":"Arch Dermatol"},{"issue":"8","key":"502_CR118","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","volume":"66","author":"J Rowin","year":"2006","unstructured":"Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006;66(8):1245\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000208416.32471.c0.","journal-title":"Neurology."},{"issue":"10","key":"502_CR119","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/acr.20212","volume":"62","author":"PA Morganroth","year":"2010","unstructured":"Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1496\u2013501. https:\/\/doi.org\/10.1002\/acr.20212.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"502_CR120","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/14397595.2013.874762","volume":"24","author":"H Tsuchiya","year":"2014","unstructured":"Tsuchiya H, Tsuno H, Inoue M, Takahashi Y, Yamashita H, Kaneko H, et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol. 2014;24(4):694\u20136. https:\/\/doi.org\/10.3109\/14397595.2013.874762.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"502_CR121","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1111\/1756-185X.13136","volume":"20","author":"J Hisanaga","year":"2017","unstructured":"Hisanaga J, Kotani T, Fujiki Y, Yoshida S, Takeuchi T, Makino S. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis. Int J Rheum Dis. 2017;20(12):2182\u20135. https:\/\/doi.org\/10.1111\/1756-185X.13136.","journal-title":"Int J Rheum Dis."},{"issue":"8","key":"502_CR122","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s10067-017-3671-0","volume":"36","author":"RVL Koyama","year":"2017","unstructured":"Koyama RVL, Braga TKK, da Silva Dias GA, Fujihara S, Fuzii HT, Yoshikawa GT. Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. Clin Rheumatol. 2017;36(8):1919\u201326. https:\/\/doi.org\/10.1007\/s10067-017-3671-0.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"502_CR123","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","volume":"150","author":"J Morisset","year":"2016","unstructured":"Morisset J, Johnson C, Rich E, Collard HR, Lee JS. Management of myositis-related interstitial lung disease. Chest. 2016;150(5):1118\u201328. https:\/\/doi.org\/10.1016\/j.chest.2016.04.007.","journal-title":"Chest"},{"issue":"Suppl. 1","key":"502_CR124","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1007\/s10875-014-0024-5","volume":"34","author":"MC Dalakas","year":"2014","unstructured":"Dalakas MC. Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. J Clin Immunol. 2014;34(Suppl. 1):S120\u20136. https:\/\/doi.org\/10.1007\/s10875-014-0024-5.","journal-title":"J Clin Immunol"},{"issue":"27","key":"502_CR125","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993\u20132000. https:\/\/doi.org\/10.1056\/NEJM199312303292704.","journal-title":"N Engl J Med"},{"issue":"4","key":"502_CR126","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaad.2013.06.007","volume":"69","author":"AN Femia","year":"2013","unstructured":"Femia AN, Eastham AB, Lam C, Merola JF, Qureshi AA, Vleugels RA. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center. J Am Acad Dermatol. 2013;69(4):654\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2013.06.007.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"502_CR127","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/jdv.12223","volume":"28","author":"T Bounfour","year":"2014","unstructured":"Bounfour T, Bouaziz JD, Bezier M, Cordoliani F, Saussine A, Petit A, et al. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease. J Eur Acad Dermatol Venereol. 2014;28(9):1150\u20137. https:\/\/doi.org\/10.1111\/jdv.12223.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"502_CR128","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314\u201324. https:\/\/doi.org\/10.1002\/art.37754.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"502_CR129","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2169\/internalmedicine.56.7956","volume":"56","author":"K Tokunaga","year":"2017","unstructured":"Tokunaga K, Hagino N. Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan. Intern Med. 2017;56(11):1399\u2013403. https:\/\/doi.org\/10.2169\/internalmedicine.56.7956.","journal-title":"Intern Med"},{"key":"502_CR130","doi-asserted-by":"publisher","first-page":"5386797","DOI":"10.1155\/2017\/5386797","volume":"2017","author":"Y Ogawa","year":"2017","unstructured":"Ogawa Y, Kishida D, Shimojima Y, Hayashi K, Sekijima Y. Effective administration of rituximab in anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease and refractory cutaneous involvement: a case report and literature review. Case Rep Rheumatol. 2017;2017:5386797. https:\/\/doi.org\/10.1155\/2017\/5386797.","journal-title":"Case Rep Rheumatol."},{"issue":"2","key":"502_CR131","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52(2):601\u20137. https:\/\/doi.org\/10.1002\/art.20849.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"502_CR132","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143(6):763\u20137. https:\/\/doi.org\/10.1001\/archderm.143.6.763.","journal-title":"Arch Dermatol"},{"issue":"4","key":"502_CR133","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","volume":"76","author":"R Shreberk-Hassidim","year":"2017","unstructured":"Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76(4):745\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.004(e19).","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"502_CR134","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005.","journal-title":"J Am Acad Dermatol"},{"issue":"26","key":"502_CR135","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","volume":"371","author":"T Hornung","year":"2014","unstructured":"Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2014;371(26):2537\u20138. https:\/\/doi.org\/10.1056\/NEJMc1412997.","journal-title":"N Engl J Med"},{"issue":"8","key":"502_CR136","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","volume":"152","author":"DJ Kurtzman","year":"2016","unstructured":"Kurtzman DJ, Wright NA, Lin J, Femia AN, Merola JF, Patel M, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2016.0866.","journal-title":"JAMA Dermatol."},{"key":"502_CR137","unstructured":"Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis. https:\/\/ClinicalTrials.gov\/show\/NCT02092467. Accessed 13 Jan 2020."},{"issue":"5","key":"502_CR138","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.transproceed.2007.11.072","volume":"40","author":"Z Kaposztas","year":"2008","unstructured":"Kaposztas Z, Etheridge WB, Kahan BD. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus. Transplant Proc. 2008;40(5):1744\u20136. https:\/\/doi.org\/10.1016\/j.transproceed.2007.11.072.","journal-title":"Transplant Proc."},{"issue":"9","key":"502_CR139","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00296-008-0822-2","volume":"29","author":"HJ Kim","year":"2009","unstructured":"Kim HJ, Hong YK, Yoo WH. Dermatomyositis, complicated with pneumomediastinum, successfully treated with cyclosporine A: a case report and review of literature. Rheumatol Int. 2009;29(9):1101\u20134. https:\/\/doi.org\/10.1007\/s00296-008-0822-2.","journal-title":"Rheumatol Int"},{"issue":"10","key":"502_CR140","first-page":"2230","volume":"28","author":"I Marie","year":"2001","unstructured":"Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28(10):2230\u20137.","journal-title":"J Rheumatol"},{"issue":"5","key":"502_CR141","first-page":"724","volume":"23","author":"O Meyer","year":"2005","unstructured":"Meyer O, Hayem G, Palazzo E, Crestani B, Debray MP, Ballard M. Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide. Clin Exp Rheumatol. 2005;23(5):724.","journal-title":"Clin Exp Rheumatol."},{"issue":"11","key":"502_CR142","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2169\/internalmedicine.44.1197","volume":"44","author":"T Mitsui","year":"2005","unstructured":"Mitsui T, Kuroda Y, Kunishige M, Matsumoto T. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med. 2005;44(11):1197\u20139.","journal-title":"Intern Med"},{"issue":"2 Suppl. 1","key":"502_CR143","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2004.05.044","volume":"52","author":"U Nadiminti","year":"2005","unstructured":"Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol. 2005;52(2 Suppl. 1):17\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2004.05.044.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"502_CR144","first-page":"707","volume":"23","author":"S Ochi","year":"2005","unstructured":"Ochi S, Nanki T, Takada K, Suzuki F, Komano Y, Kubota T, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis\/dermatomyositis. Clin Exp Rheumatol. 2005;23(5):707\u201310.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"502_CR145","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/0049-0172(90)90024-A","volume":"20","author":"G Ramirez","year":"1990","unstructured":"Ramirez G, Asherson RA, Khamashta MA, Cervera R, D\u2019Cruz D, Hughes GR. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum. 1990;20(2):114\u201320.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"502_CR146","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/art.1780360305","volume":"36","author":"PA Sinoway","year":"1993","unstructured":"Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993;36(3):319\u201324.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"502_CR147","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/030097400750001897","volume":"29","author":"J Vencovsky","year":"2000","unstructured":"Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29(2):95\u2013102.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"502_CR148","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","volume":"46","author":"Y Yamasaki","year":"2007","unstructured":"Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124\u201330. https:\/\/doi.org\/10.1093\/rheumatology\/kel112.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"502_CR149","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2169\/internalmedicine.42.1253","volume":"42","author":"Y Shimojima","year":"2003","unstructured":"Shimojima Y, Ishii W, Kato T, Hoshi K, Matsuda M, Hashimoto T, et al. Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A. Intern Med. 2003;42(12):1253\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.42.1253.","journal-title":"Intern Med"},{"issue":"9","key":"502_CR150","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00431-004-1497-7","volume":"163","author":"A Yamada","year":"2004","unstructured":"Yamada A, Ohshima Y, Omata N, Yasutomi M, Mayumi M. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr. 2004;163(9):561\u20132. https:\/\/doi.org\/10.1007\/s00431-004-1497-7.","journal-title":"Eur J Pediatr"},{"issue":"18","key":"502_CR151","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0025-7753(06)72367-3","volume":"127","author":"A Martin Nalda","year":"2006","unstructured":"Martin Nalda A, Modesto Caballero C, Arnal Guimeral C, Boronat Rom M, Barcelo Garcia P. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin (Barc). 2006;127(18):697\u2013701.","journal-title":"Med Clin (Barc)."},{"issue":"11","key":"502_CR152","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s10067-008-0973-2","volume":"27","author":"J Hassan","year":"2008","unstructured":"Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008;27(11):1469\u201371. https:\/\/doi.org\/10.1007\/s10067-008-0973-2.","journal-title":"Clin Rheumatol"},{"issue":"21","key":"502_CR153","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.2169\/internalmedicine.47.1289","volume":"47","author":"S Tsujimura","year":"2008","unstructured":"Tsujimura S, Saito K, Tanaka Y. Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy. Intern Med. 2008;47(21):1935\u201340.","journal-title":"Intern Med"},{"issue":"3","key":"502_CR154","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jaad.2007.08.014","volume":"58","author":"JS Boswell","year":"2008","unstructured":"Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol. 2008;58(3):403\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2007.08.014.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"502_CR155","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.14726","volume":"179","author":"J Callander","year":"2018","unstructured":"Callander J, Robson Y, Ingram J, Piguet V. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. Br J Dermatol. 2018;179(6):1248\u201355. https:\/\/doi.org\/10.1111\/bjd.14726.","journal-title":"Br J Dermatol"},{"issue":"3","key":"502_CR156","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1365-4362.2002.01409.x","volume":"41","author":"JB Cohen","year":"2002","unstructured":"Cohen JB. Cutaneous involvement of dermatomyositis can respond to dapsone therapy. Int J Dermatol. 2002;41(3):182\u20134.","journal-title":"Int J Dermatol"},{"issue":"4","key":"502_CR157","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2230.1994.tb01220.x","volume":"19","author":"A Konohana","year":"1994","unstructured":"Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol. 1994;19(4):367.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"502_CR158","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1136\/ard.2007.073221","volume":"67","author":"VS Sangle","year":"2008","unstructured":"Sangle VS, Sangle SR, D\u2019Cruz DP. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis. 2008;67(5):723. https:\/\/doi.org\/10.1136\/ard.2007.073221.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"502_CR159","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1744-9987.2009.00689.x","volume":"13","author":"M Sebastiani","year":"2009","unstructured":"Sebastiani M, Puccini R, Manfredi A, Manni E, Colaci M, Mattei P, et al. Staphylococcus protein A-based extracorporeal immunoadsorption and thalidomide in the treatment of skin manifestation of dermatomyositis: a case report. Ther Apher Dial. 2009;13(3):225\u20138. https:\/\/doi.org\/10.1111\/j.1744-9987.2009.00689.x.","journal-title":"Ther Apher Dial."},{"issue":"8","key":"502_CR160","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/art.1780390822","volume":"39","author":"M Zuber","year":"1996","unstructured":"Zuber M, John S, Pfreundschuh M, Gause A. A young woman with a photosensitive pruritic rash on her face and upper trunk. Arthritis Rheum. 1996;39(8):1419\u201322.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"502_CR161","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaad.2016.03.022","volume":"75","author":"Z Nahmias","year":"2016","unstructured":"Nahmias Z, Nambudiri VE, Vleugels RA. Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions. J Am Acad Dermatol. 2016;75(1):210\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2016.03.022.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"502_CR162","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1085-5629(98)80019-9","volume":"17","author":"DI Stirling","year":"1998","unstructured":"Stirling DI. Thalidomide and its impact in dermatology. Semin Cutan Med Surg. 1998;17(4):231\u201342.","journal-title":"Semin Cutan Med Surg"},{"issue":"3 Suppl. 2","key":"502_CR163","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/j.jaad.2005.11.1090","volume":"54","author":"R Norman","year":"2006","unstructured":"Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol. 2006;54(3 Suppl. 2):S139\u201342. https:\/\/doi.org\/10.1016\/j.jaad.2005.11.1090.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"502_CR164","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s00296-012-2653-4","volume":"33","author":"D Chen","year":"2013","unstructured":"Chen D, Wang XB, Zhou Y, Zhu XC. Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int. 2013;33(10):2455\u20138. https:\/\/doi.org\/10.1007\/s00296-012-2653-4.","journal-title":"Rheumatol Int"},{"issue":"7","key":"502_CR165","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s10067-006-0325-z","volume":"26","author":"S Dold","year":"2007","unstructured":"Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol. 2007;26(7):1186\u20138. https:\/\/doi.org\/10.1007\/s10067-006-0325-z.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"502_CR166","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/acr.22198","volume":"66","author":"KA Rouster-Stevens","year":"2014","unstructured":"Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2014;66(5):783\u20137. https:\/\/doi.org\/10.1002\/acr.22198.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"502_CR167","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.22477","volume":"70","author":"Muscle Study G","year":"2011","unstructured":"Muscle Study G. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70(3):427\u201336. https:\/\/doi.org\/10.1002\/ana.22477.","journal-title":"Ann Neurol"},{"issue":"7","key":"502_CR168","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3899\/jrheum.091413","volume":"37","author":"AM Brunasso","year":"2010","unstructured":"Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol. 2010;37(7):1549\u201350. https:\/\/doi.org\/10.3899\/jrheum.091413.","journal-title":"J Rheumatol"},{"issue":"12","key":"502_CR169","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670\u20137. https:\/\/doi.org\/10.1136\/ard.2007.077974.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"502_CR170","doi-asserted-by":"publisher","first-page":"R666","DOI":"10.1186\/ar1724","volume":"7","author":"M Flendrie","year":"2005","unstructured":"Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666\u201376. https:\/\/doi.org\/10.1186\/ar1724.","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"502_CR171","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/art.22358","volume":"55","author":"HA Hall","year":"2006","unstructured":"Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum. 2006;55(6):982\u20134. https:\/\/doi.org\/10.1002\/art.22358.","journal-title":"Arthritis Rheum"},{"issue":"3\u20134","key":"502_CR172","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000114036","volume":"59","author":"GJ Hengstman","year":"2008","unstructured":"Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008;59(3\u20134):159\u201363. https:\/\/doi.org\/10.1159\/000114036.","journal-title":"Eur Neurol"},{"issue":"9","key":"502_CR173","first-page":"1802","volume":"33","author":"F Iannone","year":"2006","unstructured":"Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33(9):1802\u20134.","journal-title":"J Rheumatol"},{"issue":"3","key":"502_CR174","first-page":"240","volume":"48","author":"T Ishiguro","year":"2010","unstructured":"Ishiguro T, Takayanagi N, Miyahara Y, Yanagisawa T, Sugita Y. Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi. 2010;48(3):240\u20136.","journal-title":"Nihon Kokyuki Gakkai Zasshi."},{"issue":"3","key":"502_CR175","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10067-010-1666-1","volume":"30","author":"Y Ishikawa","year":"2011","unstructured":"Ishikawa Y, Yukawa N, Kawabata D, Ohmura K, Fujii T, Usui T, et al. A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept. Clin Rheumatol. 2011;30(3):429\u201332. https:\/\/doi.org\/10.1007\/s10067-010-1666-1.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"502_CR176","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10067-009-1370-1","volume":"29","author":"Y Ishikawa","year":"2010","unstructured":"Ishikawa Y, Yukawa N, Ohmura K, Hosono Y, Imura Y, Kawabata D, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol. 2010;29(5):563\u20136. https:\/\/doi.org\/10.1007\/s10067-009-1370-1.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"502_CR177","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","volume":"146","author":"R Klein","year":"2010","unstructured":"Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146(7):780\u20134. https:\/\/doi.org\/10.1001\/archdermatol.2010.142.","journal-title":"Arch Dermatol"},{"issue":"6","key":"502_CR178","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1080\/03009740701281293","volume":"36","author":"E Liozon","year":"2007","unstructured":"Liozon E, Ouattara B, Loustaud-Ratti V, Vidal E. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scand J Rheumatol. 2007;36(6):484\u20136. https:\/\/doi.org\/10.1080\/03009740701281293.","journal-title":"Scand J Rheumatol"},{"issue":"10","key":"502_CR179","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1001\/jamadermatol.2013.5220","volume":"149","author":"SW Liu","year":"2013","unstructured":"Liu SW, Velez NF, Lam C, Femia A, Granter SR, Townsend HB, et al. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol. 2013;149(10):1204\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5220.","journal-title":"JAMA Dermatol."},{"issue":"12","key":"502_CR180","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/rheumatology\/keg388","volume":"42","author":"J Musial","year":"2003","unstructured":"Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford). 2003;42(12):1566\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keg388.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"502_CR181","first-page":"192","volume":"39","author":"G Riolo","year":"2012","unstructured":"Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol. 2012;39(1):192\u20134.","journal-title":"J Rheumatol"},{"issue":"6","key":"502_CR182","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s10165-006-0523-1","volume":"16","author":"Y Urata","year":"2006","unstructured":"Urata Y, Wakai Y, Kowatari K, Nitobe T, Mizushima Y. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol. 2006;16(6):410\u20131. https:\/\/doi.org\/10.1007\/s10165-006-0523-1.","journal-title":"Mod Rheumatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00502-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-020-00502-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00502-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:00:53Z","timestamp":1659088853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-020-00502-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":182,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00502-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"24 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gabriela A. Cobos has no conflicts of interest that are directly relevant to the content of this article. Alisa Femia is a principal investigator for a Pfizer-sponsored trial on dermatomyositis treatment. Ruth Ann Vleugels is a principal investigator for a Pfizer-sponsored trial on dermatomyositis treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}